Back to Authors

Wang, Xiaojie

Mayo Clinic

University of Miami

Citations 1

TDP-43 subtypes shape transcriptomic signatures in Alzheimer’s disease
Wang, Xiaojie, Reeves, Madison M, Bejarano, Jesús González , Song, Yuping , Dunmore, Judy, Yue, Mei, Rawlinson, Bailey, DeTure, Michael, Tome, Raul Baena, Narayan, Anand, Bartfield, Jordan, Graff‐Radford, Neill R. , Peterson, Ronald C. , Oskarsson, Björn, Murray, Melissa E, Dickson, DW, Cook, Casey, Zhang, Yongjie, Petrucelli, Leonard , Josephs, Keith A, Walker, Alyssa C. , Reeves, Madison M., Dunmore, Judy H., Yue, Mei, Rawlinson, Bailey, Engelberg-Cook, Erica , DeTure, Michael , Narayan, Anand, Boeve, Bradley F. , Knopman, David S. , Day, Gregory S. , Murray, Melissa E. , Dickson, Dennis W. , Josephs, Keith A. , Prudencio, Mercedes

No container title available | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.22.733827 Get It

Abstract TAR DNA-binding protein 43 (TDP-43) pathology frequently co-occurs with Tau neurofibrillary tangles (NFTs) and amyloid β plaques in Alzheimer’s disease (AD), driving significant clinical heterogeneity. Whether TDP-43 engages autonomous molecular programs or instead amplifies Tau-driven neurodegeneration remains difficult to resolve, largely because these pathologies often co-occur. To separate these overlapping signatures, we generated regionally resolved transcriptomic profiles from cognitively normal controls (Controls), neuropathologically defined cohorts of AD, AD with limbic-predominant age-related TDP-43 encephalopathy (AD/LATE), and frontotemporal lobar degeneration (FTLD-TDP), categorizing them by their distinct TDP-43 subtypes (types α and β for AD/LATE; types A and B for FTLD-TDP). By integrating transcriptomic profiles with quantitative measures of phosphorylated TDP-43 (pTDP-43) and Tau (pTau), we separated pathology-associated signals within mixed disease contexts. We found that TDP-43 is linked to distinct transcriptomic programs in AD/LATE that are largely uncoupled from Tau burden and diverge from those observed in FTLD-TDP. These signatures showed regional specificity, with transcriptomic remodeling occurring in the amygdala across both diseases, whereas frontal cortex alterations were largely restricted to FTLD-TDP. Furthermore, by stratifying cases by TDP-43 morphological subtype, we unmasked specific biological trajectories, from immune activation to unique cellular vulnerabilities, that are not apparent in unstratified cohorts. Together, our findings provide a framework for decoupling mixed proteinopathies and demonstrate that TDP-43 shapes autonomous, subtype-dependent transcriptional landscapes in AD.